Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.33 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12665273 | 0.94 | CYP2C8 (0.48) | CYP2C8PLA2G2AKMT2AS1PR3MEN1 | |
| SCHEMBL13906260 | 0.92 | CYP2C8 (0.40) | CYP2C8PLA2G2AKMT2AS1PR3MEN1 | |
| SCHEMBL12665816 | 0.91 | CYP2C8 (0.40) | CYP2C8PLA2G2AKMT2AMEN1MAPT | |
| SCHEMBL12665807 | 0.90 | CYP2C8 (0.43) | CYP2C8PLA2G2AKMT2AMEN1MAPT | |
| SCHEMBL832281 | 0.89 | CYP2C8 (0.38) | CYP2C8PLA2G2AKMT2AS1PR3MEN1 | |
| SCHEMBL12665817 | 0.88 | CYP2C8 (0.40) | CYP2C8KMT2AMEN1MAPTLMNA | |
| SCHEMBL12665811 | 0.87 | CYP2C8 (0.54) | CYP2C8PLA2G2AKMT2AS1PR3MEN1 | |
| SCHEMBL12665805 | 0.87 | CYP2C8 (0.45) | CYP2C8KMT2AMEN1MAPTKDM4E | |
| SCHEMBL832072 | 0.86 | CYP2C8 (0.36) | CYP2C8PLA2G2AKMT2AS1PR3 | |
| SCHEMBL13906262 | 0.85 | CYP2C8 (0.47) | CYP2C8PLA2G2AKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SHERING CORPORATION | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | CYP2C8 457/4885PLA2G2A 4022/4885KMT2A 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.